{
    "clinical_study": {
        "@rank": "127683", 
        "arm_group": {
            "arm_group_label": "Optivate 500IU", 
            "arm_group_type": "Experimental", 
            "description": "Optivate 500IU"
        }, 
        "brief_summary": {
            "textblock": "Primary objective: To assess post-marketing immunogenicity of Optivate\u00ae by monitoring plasma\n      inhibitor levels for at least 100 Exposure Days (EDs) for each subject.\n\n      Secondary objectives: To assess efficacy and tolerability by monitoring FVIII recovery and\n      adverse events"
        }, 
        "brief_title": "Multicentre, Non-controlled, Prospective, Post-Marketing Safety Study Following Long-Term Prophylactic OptivateTreatment in Subjects With Severe Haemophilia A", 
        "completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Haemophilia A", 
        "condition_browse": {
            "mesh_term": "Hemophilia A"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Written informed consent or, if less than 18 years of age written assent  (where\n             possible) and their parent/guardian's written informed consent.\n\n          -  Severe haemophilia A (< 1%# FVIII:C).\n\n          -  Previously Treated Patients (PTPs) with > 150 exposure days on prior Factor VIII\n             therapy (of which at least the last 50 EDs or 2 years treatment can be confirmed by\n             way of subject records).\n\n          -  Immunocompetent with CD4 count > 200 / \u00b5l.\n\n          -  HIV negative or a viral load < 200 particles / \u00b5l.\n\n               -  subjects suffering from severe haemophilia A (<2%) may be enrolled, but only\n                  after approval by BPL.  Subjects with a Factor VIII of <2% may not constitute\n                  more than 50% of the total patient population.  A separate statistical\n                  evaluation will be conducted for the <1% and <2% populations.\n\n        Exclusion Criteria:\n\n          -  \u2022 History of inhibitor development to FVIII or a positive result on the Nijmegen\n             Bethesda at screening (quantitative result of > 0.6 BU) prior to the administration\n             of Optivate\u00ae.\n\n               -  Known or suspected hypersensitivity to the investigational medicinal product or\n                  its excipients.\n\n               -  Clinically significant liver disease, renal disease, or coagulopathy other than\n                  haemophilia A.\n\n               -  History of unreliability or non cooperation (including not being able to\n                  complete the study diary).\n\n               -  Participating in, or have taken part in another trial within the last 30 days."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "firstreceived_date": "March 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01811875", 
            "org_study_id": "8VWF07"
        }, 
        "intervention": {
            "arm_group_label": "Optivate 500IU", 
            "intervention_name": "Optivate 500IU", 
            "intervention_type": "Biological"
        }, 
        "intervention_browse": {
            "mesh_term": "Factor VIII"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Haemophilia A", 
        "lastchanged_date": "March 18, 2013", 
        "location": {
            "contact": {
                "last_name": "To be assigned"
            }, 
            "facility": {
                "address": {
                    "city": "To be assigned", 
                    "country": "Germany"
                }, 
                "name": "To be assigned"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "official_title": "Multicentre, Non-controlled, Prospective, Post-Marketing Safety Study Following Long-Term Prophylactic OptivateTreatment in Subjects With Severe Haemophilia A", 
        "overall_contact": {
            "email": "tim.aldwinckle@bpl.co.uk", 
            "last_name": "Tim Aldwinckle, Dr", 
            "phone": "+44(0) 208 957 2200"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Germany: Paul-Ehrlich-Institut", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "To assess post-marketing immunogenicity of Optivate by monitoring plasma inhibitor levels for at least 100 Exposure Days for each subject.", 
            "safety_issue": "Yes", 
            "time_frame": "At least 100 Exposure Days for each subject. Subjects will attend 5 visits over a period of up to 12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01811875"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "To assess efficacy and tolerability", 
            "safety_issue": "Yes", 
            "time_frame": "Over a period of 12 months"
        }, 
        "source": "Bio Products Laboratory", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bio Products Laboratory", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }
}